Examkin

Soru

Zorluk: ZorStudy Design

A pharmaceutical company submits a trial protocol to regulatory authorities for a new once-daily oral antibiotic intended for uncomplicated *Staphylococcus aureus* bacteremia. The current standard of care is a 14-day course of intravenous (IV) antibiotics. The trial is designed to demonstrate that the new oral antibiotic is clinically acceptable and no worse than the IV standard by a pre-specified margin of 10% for the primary outcome of 30-day clinical cure. If successful, this drug would significantly reduce hospital length of stay.

In this specific type of trial design, which of the following methodological approaches is most critical to minimize the risk of falsely concluding the oral antibiotic is as effective as the intravenous standard?

  1. Conducting the primary efficacy analysis on the per-protocol populationCevap
  2. B
    Relying exclusively on the intention-to-treat population for the primary analysis
  3. C
    Transitioning patients to a crossover design halfway through the treatment period
  4. D
    Expanding the pre-specified non-inferiority margin to 15% to increase statistical power
  5. E
    Utilizing a matched historical cohort for the standard of care arm

Cevap

Conducting the primary efficacy analysis on the per-protocol population
In a non-inferiority trial, the goal is to demonstrate that a new treatment is not unacceptably worse than the standard of care. Any factor that dilutes the treatment effect (such as medication non-adherence, protocol violations, or loss to follow-up) will make the two study groups appear more similar. Because making the groups look similar biases the results toward the null (no difference), this increases the risk of a Type I error—falsely concluding that an inferior drug is non-inferior. Therefore, unlike superiority trials where an intention-to-treat (ITT) analysis is conservative, non-inferiority trials must prioritize a per-protocol (PP) analysis. The PP analysis only includes patients who strictly adhered to the protocol, providing a more conservative and accurate estimate of the true treatment effect in this specific trial design. Regulatory guidelines typically require both ITT and PP analyses to concordantly demonstrate non-inferiority.

Adım Adım Çözüm

1
Identify the study design from the scenario.
The trial aims to show a new drug is 'no worse than' the standard by a 'pre-specified margin'. This defines a non-inferiority trial.
Understanding the core objective of the trial dictates the appropriate statistical methodology.
2
Determine the statistical goal of a non-inferiority trial.
The goal is to reject the null hypothesis that the new drug is inferior to the standard of care by more than the 10% margin.
This establishes what constitutes a Type I error (falsely claiming the drug is acceptable when it is actually inferior).
3
Analyze how protocol deviations affect the results.
Factors like non-adherence, dropouts, or cross-overs dilute the true treatment effect, making the two study arms appear more similar to each other (biasing toward the null).
In non-inferiority trials, biasing toward the null makes it easier to achieve the study's goal, which is dangerous as it can lead to approving an inferior drug.
4
Select the conservative analysis population.
An intention-to-treat (ITT) analysis includes all violators and biases toward the null. A per-protocol (PP) analysis excludes violators and highlights the true difference. Therefore, a PP analysis is the conservative and critical approach.
PP analysis minimizes the risk of falsely concluding non-inferiority, which is the primary concern in this trial design.

Anahtar Kavram

Analysis populations in non-inferiority trials
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Study Design

Bu konudan daha fazla soru